Each week on DocWire News, editors bring you the latest hematology and oncology news and research. In case you missed it, here are this week’s top headlines.
Here are the highlights:
- Best of the International Myeloma Workshop with Dr. Manni Mohyuddin
- NCI-funded Trials Network has Added 14 Million Years of Life to Cancer Patients
- Improving Diversity in Smoking Cessation Trials
- Fear of Recurrence Persists for Some Prostate Cancer Survivors
Keep reading for the breakdown on these top stories in cancer research and news!
Best of the International Myeloma Workshop with Dr. Manni Mohyuddin
This week on DocWire, Dr. Manni Mohyuddin summarized the most important updates from the 2021 International Myeloma Workshop meeting, including the latest findings on minimal residual disease as a surrogate of survival in multiple myeloma, 1q gain during the course of therapy, patient trajectories after CAR T cell infusion, and more. Read Dr. Mohyuddin’s full breakdown of the meeting:
NCI-funded Trials Network has Added 14 Million Years of Life to Cancer Patients
In other oncology news, data presented at the ESMO Annual Meeting showed that, over the past 40 years, people in the U.S. diagnosed with cancer gained 14 million years of additional life thanks to the results of cancer clinical trials funded by the National Cancer Institute’s National Clinical Trials Network (NCTN).
The researchers also found the published results of this cancer research have been cited more than 166,000 times, and more than 80% of the studies influenced treatment guideline recommendations, demonstrating the profound scientific impact of these trials on cancer research and care over the decades.
“The results from these cancer clinical trials reflect the experience of participants from both community and academic sites and show a dramatic gain in years of life,” said Dr. Meg Mooney, associate director of the National Cancer Institute’s Cancer Therapy Evaluation Program. “This work demonstrates the impact that cancer clinical trials conducted broadly on a national scale have on the field of cancer research and on people with cancer.”
Improving Diversity in Smoking Cessation Trials
A study evaluated the efficacy of strategies meant to improve the recruitment of racially and ethnically diverse participants in smoking cessation trials. Reactive strategies, such as flyers, ads, and word-of-mouth, yielded dramatically higher enrollment rates compared to direct invitations to the trial (94.3% vs. 5.7%).
Word-of-mouth, proactive recruitment (direct invitations), and flyers were more successful among African American individuals compared to other racial/ethnic groups. Newspaper and online ads were more successful among Hispanic/Latinx participants than for other races. Word-of-mouth, which was cost-free, yielded 23.1% of enrollment. Among paid strategies, the most economical methods were flyer distribution, newspaper ads, and online ads. Radio and television ads were the most expensive methods and led to the lowest participant yield.
Fear of Recurrence Persists for Some Prostate Cancer Survivors
Finally, for prostate cancer survivors after radical prostatectomy, fear of cancer recurrence remains a burden, even years after diagnosis. Of more than 2,400 participants with a history of prostate cancer surveyed, 6.5 percent reported clinical fear of recurrence after around seven years after prostatectomy. Participants were surveyed again nine years after their initial responses, and the rate of fear of recurrence rose to 8.4 percent. Factors that were predictive for fear of recurrence included lower education levels, years since surgery, biochemical recurrence, no current adjuvant therapy, initial fear at first survey, and anxiety.
“Treating health care professionals should be aware of these factors in clinical practice to provide appropriate psychosocial care when needed because fear of cancer recurrence is among the most endorsed unmet needs and concerns in cancer survivors,” wrote the study authors.